• Something wrong with this record ?

The nascent polypeptide-associated complex (NAC) controls translation initiation in cis by recruiting nucleolin to the encoding mRNA

AJL. Zheng, A. Thermou, C. Daskalogianni, L. Malbert-Colas, K. Karakostis, R. Le Sénéchal, V. Trang Dinh, MC. Tovar Fernandez, S. Apcher, S. Chen, M. Blondel, R. Fahraeus

. 2022 ; 50 (17) : 10110-10122. [pub] 2022Sep23

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22024358

Grant support
FDT202001010912 Université de Paris and the Fondation pour la Recherche Médicale
CZ.02.1.01/0.0/0.0/16_019/0000868 European Regional Development Fund
00209805 MH CZ - DRO
160598 Cancerforskningsfonden Norr, Cancerfonden
International Centre for Cancer Vaccine Science

Protein aggregates and abnormal proteins are toxic and associated with neurodegenerative diseases. There are several mechanisms to help cells get rid of aggregates but little is known on how cells prevent aggregate-prone proteins from being synthesised. The EBNA1 of the Epstein-Barr virus (EBV) evades the immune system by suppressing its own mRNA translation initiation in order to minimize the production of antigenic peptides for the major histocompatibility (MHC) class I pathway. Here we show that the emerging peptide of the disordered glycine-alanine repeat (GAr) within EBNA1 dislodges the nascent polypeptide-associated complex (NAC) from the ribosome. This results in the recruitment of nucleolin to the GAr-encoding mRNA and suppression of mRNA translation initiation in cis. Suppressing NAC alpha (NACA) expression prevents nucleolin from binding to the GAr mRNA and overcomes GAr-mediated translation inhibition. Taken together, these observations suggest that EBNA1 exploits a nascent protein quality control pathway to regulate its own rate of synthesis that is based on sensing the nascent GAr peptide by NAC followed by the recruitment of nucleolin to the GAr-encoding RNA sequence.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024358
003      
CZ-PrNML
005      
20221031100312.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/nar/gkac751 $2 doi
035    __
$a (PubMed)36107769
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Zheng, Alice J L $u Inserm UMRS 1131, Institut de Génétique Moléculaire, Université de Paris, Hôpital St. Louis, F-75010 Paris, France
245    14
$a The nascent polypeptide-associated complex (NAC) controls translation initiation in cis by recruiting nucleolin to the encoding mRNA / $c AJL. Zheng, A. Thermou, C. Daskalogianni, L. Malbert-Colas, K. Karakostis, R. Le Sénéchal, V. Trang Dinh, MC. Tovar Fernandez, S. Apcher, S. Chen, M. Blondel, R. Fahraeus
520    9_
$a Protein aggregates and abnormal proteins are toxic and associated with neurodegenerative diseases. There are several mechanisms to help cells get rid of aggregates but little is known on how cells prevent aggregate-prone proteins from being synthesised. The EBNA1 of the Epstein-Barr virus (EBV) evades the immune system by suppressing its own mRNA translation initiation in order to minimize the production of antigenic peptides for the major histocompatibility (MHC) class I pathway. Here we show that the emerging peptide of the disordered glycine-alanine repeat (GAr) within EBNA1 dislodges the nascent polypeptide-associated complex (NAC) from the ribosome. This results in the recruitment of nucleolin to the GAr-encoding mRNA and suppression of mRNA translation initiation in cis. Suppressing NAC alpha (NACA) expression prevents nucleolin from binding to the GAr mRNA and overcomes GAr-mediated translation inhibition. Taken together, these observations suggest that EBNA1 exploits a nascent protein quality control pathway to regulate its own rate of synthesis that is based on sensing the nascent GAr peptide by NAC followed by the recruitment of nucleolin to the GAr-encoding RNA sequence.
650    _2
$a alanin $7 D000409
650    12
$a infekce virem Epsteina-Barrové $7 D020031
650    _2
$a virus Epsteinův-Barrové - jaderné antigeny $x metabolismus $7 D019309
650    _2
$a glycin $7 D005998
650    12
$a virus Epsteinův-Barrové $x genetika $7 D004854
650    _2
$a lidé $7 D006801
650    _2
$a peptidy $x genetika $7 D010455
650    _2
$a fosfoproteiny $7 D010750
650    _2
$a proteinové agregáty $7 D066329
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a proteiny vázající RNA $x metabolismus $7 D016601
655    _2
$a časopisecké články $7 D016428
700    1_
$a Thermou, Aikaterini $u Inserm UMRS 1131, Institut de Génétique Moléculaire, Université de Paris, Hôpital St. Louis, F-75010 Paris, France $u ICCVS, University of Gdańsk, Science, ul. Wita Stwosza 63, 80-308 Gdańsk, Poland
700    1_
$a Daskalogianni, Chrysoula $u Inserm UMRS 1131, Institut de Génétique Moléculaire, Université de Paris, Hôpital St. Louis, F-75010 Paris, France $u ICCVS, University of Gdańsk, Science, ul. Wita Stwosza 63, 80-308 Gdańsk, Poland
700    1_
$a Malbert-Colas, Laurence $u Inserm UMRS 1131, Institut de Génétique Moléculaire, Université de Paris, Hôpital St. Louis, F-75010 Paris, France
700    1_
$a Karakostis, Konstantinos $u Inserm UMRS 1131, Institut de Génétique Moléculaire, Université de Paris, Hôpital St. Louis, F-75010 Paris, France $1 https://orcid.org/0000000311227860
700    1_
$a Le Sénéchal, Ronan $u Inserm UMR 1078, Université de Bretagne Occidentale (UBO), Etablissement Français du Sang (EFS) Bretagne, CHRU Brest, 29200, Brest, France
700    1_
$a Trang Dinh, Van $u Inserm UMR 1078, Université de Bretagne Occidentale (UBO), Etablissement Français du Sang (EFS) Bretagne, CHRU Brest, 29200, Brest, France
700    1_
$a Tovar Fernandez, Maria C $u Inserm UMRS 1131, Institut de Génétique Moléculaire, Université de Paris, Hôpital St. Louis, F-75010 Paris, France $u ICCVS, University of Gdańsk, Science, ul. Wita Stwosza 63, 80-308 Gdańsk, Poland
700    1_
$a Apcher, Sébastien $u Institut Gustave Roussy, Université Paris Sud, Unité 1015 département d'immunologie, 114, rue Edouard Vaillant, 94805 Villejuif, France
700    1_
$a Chen, Sa $u Department of Medical Biosciences, Building 6M, Umeå University, 901 85 Umeå, Sweden
700    1_
$a Blondel, Marc $u Inserm UMR 1078, Université de Bretagne Occidentale (UBO), Etablissement Français du Sang (EFS) Bretagne, CHRU Brest, 29200, Brest, France $1 https://orcid.org/0000000348972995
700    1_
$a Fahraeus, Robin $u Inserm UMRS 1131, Institut de Génétique Moléculaire, Université de Paris, Hôpital St. Louis, F-75010 Paris, France $u Department of Medical Biosciences, Building 6M, Umeå University, 901 85 Umeå, Sweden $u RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653 Brno, Czech Republic $1 https://orcid.org/0000000304028492
773    0_
$w MED00003554 $t Nucleic acids research $x 1362-4962 $g Roč. 50, č. 17 (2022), s. 10110-10122
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36107769 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100310 $b ABA008
999    __
$a ok $b bmc $g 1854210 $s 1175648
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 50 $c 17 $d 10110-10122 $e 2022Sep23 $i 1362-4962 $m Nucleic acids research $n Nucleic Acids Res $x MED00003554
GRA    __
$a FDT202001010912 $p Université de Paris and the Fondation pour la Recherche Médicale
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000868 $p European Regional Development Fund
GRA    __
$a 00209805 $p MH CZ - DRO
GRA    __
$a 160598 $p Cancerforskningsfonden Norr, Cancerfonden
GRA    __
$p International Centre for Cancer Vaccine Science
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Archiving options